Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PRQR
SellProQR Therapeutics N.V. · Healthcare · Netherlands · $323M · Avg Vol: $2M/d
COMPANY DESCRIPTION
ProQR Therapeutics N.V. is a clinical-stage biotechnology company developing RNA therapies for severe genetic eye diseases. Its lead programs target rare inherited retinal disorders using proprietary RNA repair and modulation technologies. ProQR is a niche player focused on high unmet medical needs within ophthalmology, aiming to provide disease-modifying treatments for conditions with limited or no existing therapies.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.2M | 7.6M | 21.9M | 18.5M | 64.2% | 21.5M | 20.2M | 18.2M | -0.7% |
| EPS | -1.04 | -0.41 | -0.37 | -0.46 | — | -0.47 | -0.54 | -0.55 | — |
| Shares | 80.8M | 81.4M | 105.2M | 105.4M | +30.4% | 141.1M | — | — | — |
| Debt | 25.5M | 22.9M | 20.0M | 18.5M | -10.1% | 17.9M | — | — | — |
| Equity | 77.8M | 48.0M | 102.7M | 57.3M | -9.7% | — | — | — | — |
| Op CF | -79.5M | 25.0M | -42.2M | -61.2M | — | -57.2M | — | — | — |
| Inv CF | -0.8M | 5.0M | -4.7M | -1.2M | — | — | — | — | — |
| Fin CF | -35.8M | -2.6M | 81.5M | -2.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PRQR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PRQR | ProQR Therapeutics N.V.(you) | $323M | 29 | Sell |
| PHARM.AS | Pharming Group N.V. | $815M | 35 | Sell |
| ONWD.BR | Onward Medical N.V. | $199M | 4 | Strong Sell |
| QURE | uniQure N.V. | $3.4B | 18 | Strong Sell |
| NAMS | NewAmsterdam Pharma Company N.V. | $3.0B | 9 | Strong Sell |
| ARGX | argenx SE | $63.6B | 75 | Buy |
| RDC.DE | Redcare Pharmacy NV | $1.5B | 53 | Hold |
| QGEN | Qiagen N.V. | $8.9B | 65 | Hold |
| PHG | Koninklijke Philips N.V. | $26.1B | 84 | Strong Buy |
Peer medians: ROE 10.2% · P/E 22.2x · Gross margin 66.4%